In this guest analysis, Scott Mazza, co-founder of Vitality CBD, examines what emerging clinical evidence does and does not establish about CBD and anxiety, citing a Phase 2 trial in which low-dose, full-spectrum CBD oil was associated with significant symptom reduction alongside reported improvements in mood, sleep, and cognitive function. Mazza uses those findings to argue that full-spectrum formulations may hold advantages over isolates, and calls for the continued clinical research needed to establish standardized dosing before results like these can support any therapeutic guidance.

In this expert analysis, Scott Mazza, co-founder of Vitality CBD, examines the emerging science behind CBD use in pets, with a focus on arthritis, inflammation, and anxiety. Drawing on early peer-reviewed studies and veterinary insights, Mazza outlines evidence-based dosing considerations and stresses the importance of organic, lab-tested, pet-specific formulations as consumer interest in animal CBD wellness accelerates in the UK and globally.

In this guest column, Scott Mazza of Vitality CBD examines emerging preclinical research on CBD’s potential role in alleviating menopause-related symptoms. Citing a first-of-its-kind study published in Frontiers in Pharmacology, Mazza explains how CBD influenced metabolism, inflammation, bone density, and gut health in estrogen-deficient models, while emphasizing the need for further human research, rigorous product standards, and third-party testing as interest in CBD-based menopause support continues to grow.

In this lifestyle review, Mom Does Reviews covers Vitality CBD’s salves for an audience of parents who want something they can apply quickly and then forget about. The piece is specific about composition: U.S.-sourced hemp, full-spectrum extract, organic ingredients, CO₂ extraction. It is specific too about the salves being non-psychoactive, generally the first question this readership asks, and it treats those verifiable details as the reason to consider the brand rather than any account of what the product does.

In this op-ed, Scott Mazza of Vitality CBD examines Canada’s cannabis legalization missteps to outline practical lessons for New York as it rolls out adult-use sales. Drawing on Canada’s experience with overproduction, overregulation, and persistent illicit markets, Mazza argues that balanced supply, flexible regulation, and meaningful inclusion of legacy operators are essential to building a sustainable, competitive legal cannabis market in New York.

In this guest column, Scott Mazza, co-founder and COO of Vitality CBD, outlines three key policy changes he believes should be addressed in the 2023 Farm Bill to bring clarity and stability to the CBD market. Mazza argues for FDA approval of CBD as a dietary supplement, clear federal treatment of Delta-8 THC, and a revised THC threshold for hemp, positioning regulatory certainty as essential for consumer safety, product quality, and long-term industry growth.

In this product review, It’s Free At Last covers Vitality CBD’s USDA-certified organic oils and full-spectrum salves within a broader piece on evening and stress-related wellness routines. The review’s attention is on what can be checked rather than what is claimed: third-party lab testing, organic sourcing, and cannabinoid content stated plainly on the label, which the writer treats as the practical way to choose between products in a category where labeling is frequently inaccurate.

In this curated self-care and wellness guide, Posh Beauty Blog features Vitality CBD Salve as a premium topical option, highlighting its organic ingredients, USDA Organic certification, and third-party lab testing. The article positions Vitality CBD as a clean, trustworthy choice within a broader lifestyle and beauty context, emphasizing product purity, potency, and safety for consumers seeking high-quality CBD solutions as part of their everyday wellness routines.

In this guest column, Scott Mazza, co-founder and COO of Vitality CBD, examines what current research does—and does not—tell us about CBD salves for pain management and athletic recovery. Mazza outlines the compound’s anti-inflammatory potential, growing adoption among professional athletes, and the need for stronger clinical evidence and product standards, emphasizing third-party testing and quality controls as essential safeguards as interest in CBD-based alternatives to opioids continues to grow.

In this op-ed, Scott Mazza, co-founder and COO of Vitality CBD, argues that continued FDA inaction on approving CBD as a dietary supplement is putting consumers at risk and undermining industry credibility. Mazza explains how the lack of federal standards enables unsafe products and misleading claims, and calls for clear regulatory approval to legitimize CBD, protect consumers, and support evidence-based research and responsible manufacturers.

In this guest column, Scott Mazza of Vitality CBD examines the growing acceptance of CBD in professional sports following Major League Baseball’s decision to allow CBD sponsorships. Drawing on developments across the MLB, NFL, and UFC, Mazza explains why CBD aligns with athlete recovery and consumer awareness, while outlining the regulatory and advertising constraints companies must navigate as CBD enters mainstream sports media.

The Buffalo News reports on the scramble among small retailers to position themselves ahead of New York’s adult-use cannabis launch, with licensing timelines still unsettled. Scott Mazza of Vitality CBD comments on what that uncertainty means for independent operators trying to plan retail entry without knowing when, or on what terms, the market will open.